Listen on the go
    • CORRECT!
    Next question
    Faculty & Disclosures
    Dr Antonella Cianferoni

    Children’s Hospital of Philadelphia, PA, USA

    Dr Cianferoni is an associate professor in paediatrics at the Perelman School of Medicine, University of Pennsylvania and the Medical Director of the Food Allergy Immunotherapy Program at the Children’s Hospital of Philadelphia (CHOP), PA, USA. She is board-certified by the American Board of Allergy and Immunology and is a practising paediatric allergist with a special clinical and research interest in food allergy, both IgE- and non-IgE-mediated. read more

    Dr Cianferoni obtained her MD, PhD, at the University of Florence, Italy; she then completed a research fellowship at Johns Hopkins Allergy Center, Baltimore, MD, followed by a residency in paediatrics at CHOP and an allergy and immunology fellowship at Boston Children’s Hospital, MA, before finally joining the faculty of the Allergy and Immunology Division in the Department of Pediatrics at CHOP.

    She was the first person to describe how iNKT and T cells contribute to food allergy pathogenesis, including EoE and IgE-mediated food allergies. Dr Cianferoni also contributed to the identification of TSLP, EMSY and CAPN14 as genetic risk factors for EoE. She was the primary investigator in the first ever study aimed at modifying the course of EoE by inducing tolerance to milk allergen with epicutaneous immunotherapy, and is the co-investigator in many other clinical trials.

    Based on her work at CHOP, Dr Cianferoni has developed the multifood immunology protocol to treat patients with complex food allergies, and she is currently studying the safety and efficacy of such protocols and how they influence the development of EoE.

    Dr Cianferoni is the past chair of the BCI Section at the American Academy of Allergy, Asthma & Immunology, a member of the Eosinophilic Esophagitis Working Group at the European Academy of Allergy & Clinical Immunology, and a member of the medical board in the International FPIES Association.

    Dr Antonella Cianferoni discloses: Advisory board or panel fees from Sanofi (relationship terminated). Consultancy fees from AstraZeneca and Sanofi (all relationships terminated).
    touchIMMUNOLOGY touchIMMUNOLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:
    More Conferences

    • Allergic Conditions

    EU PARTNER

    Allergy

    The incidence of allergies is increasing, particularly in industrialized areas. Allergic inflammation can differ substantially in intensity. Traditional drug therapy such as antihistamines, corticosteroids, anticholinergic agents and leukotriene inhibitors is important in reducing and preventing symptoms and is essential in acute use. More recent therapies including anti-immunoglobin E (IgE) therapy, anti-interleukin (IL) monoclonal antibodies, and phosphodiesterase 4/phospholipaseA2 inhibitors, have improved outcomes. However, in order to develop more effective therapies, further research is needed into the molecular mechanisms underlying allergy onset, particularly in terms of intracellular reactions and the cytosolic Ca2+ balance.

    Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Allergic Conditions Content

    Allergic Conditions
    Watch Time: 16 mins
    touchFOCUS
    Expert insights in food allergy: Considerations for diagnosis and management in primary care and beyond
    CE/CME ACCREDITED Dr Antonella Cianferoni

    An allergist shares her expert insights on the latest guidance for the diagnosis and management of food allergies, including the role of novel diagnostic tools and emerging therapies in clinical practice.

    Learning objectives
    Learning Objectives
    • Discuss evolving guidance in the prevention and diagnosis of food allergies
    • Summarize interdisciplinary strategies for personalizing the management of patients with food allergies
    Allergic Conditions, Atopic Dermatitis, Paediatric Dermatology
    Watch Time: 16 mins
    touchFOCUS
    Addressing the diagnosis and management of pet allergies in primary care and beyond
    CE/CME ACCREDITED Dr Ann-Marie Malby Schoos

    An allergist shares her expert insights and guidance on key clinical questions around the changing paradigm in the diagnosis and management of pet allergies.

    Learning objectives
    Learning Objectives
    • Interpret advances in the diagnosis of pet allergies and how these fit into the current diagnostic paradigm
    • Summarize optimal strategies for the management of pet allergies, including effective control measures and treatments
    Allergic Conditions, Digestive Disorders
    Watch Time: 34 mins
    touchEXPERT OPINIONS
    Diagnosing and treating patients with EoE: Tackling the difficulties
    CE/CME ACCREDITED Dr Efrem Eren, Dr Nirmala Gonsalves, Dr Jamal Hayat Translations available:

    Three experts discuss the challenges related to recognizing, diagnosing and treating patients with eosinophilic oesophagitis (EoE) and highlight how advances in diagnostic tools and emerging treatments may impact future care.

    Learning objectives
    Learning Objectives
    • Identify key clinical features of EoE in children and adults
    • Explain the diagnostic pathway for EoE and define the usefulness of minimally-invasive tests and tools for diagnosis and monitoring of EoE
    • Summarize the efficacy and safety data for biologics in patients with EoE
    Allergic Conditions, Urticaria
    Developed by Touch
    CRUSE® app, for the management of chronic spontaneous urticaria: Marcus Maurer
    Watch Time: 3 mins

    The CRUSE® app has been developed for the self-management of chronic spontaneous urticaria (CSU), and to help physicians develop personalised treatment strategies for patients. touchIMMUNOLOGY were delighted to speak with Prof. Marcus Maurer (Professor of Dermatology and Allergy, Charité – Universitätsmedizin Berlin) about the availability, functions, and clinical implications of the app. Questions: Please could you […]

    Allergic Conditions
    Developed by Touch
    William R. Lumry, AAAAI 2023: Lanadelumab for paediatric patients aged 2 to <12 years with hereditary angioedema – the SPRING Study
    Watch Time: 8 mins

    The SPRING Study (NCT04070326) was a phase 3 study that investigated the safety, pharmacokinetics, and pharmacodynamics of lanadelumab for prevention of hereditary angioedema (HAE) attacks in children. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the aims, design and findings from the SPRING Study and how […]

    Allergic Conditions
    Developed by Touch
    William R. Lumry, AAAAI 2023: Current treatment paradigm and unmet needs in hereditary angioedema
    Watch Time: 5 mins

    Hereditary angioedema (HAE) is a rare genetic disease that reduces C1 inhibitor levels and impacts the regulation of several pathways involved in dilation of the blood vessels and results in recurrent episodes of  severe swelling. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the unmet needs […]

    Allergic Conditions
    Developed by Touch
    Ralph Mösges, AAAAI 2023: Mannan conjugated birch pollen allergoids for the treatment of birch pollen allergy
    Watch Time: 8 mins

    Mannan conjugated birch pollen allergoids are an immunotherapy currently under clinical investigation for the treatment of birch pollen allergy. touchIMMUNOLOGY caught up with Prof. Ralph Mösges (University of Cologne, Cologne, Germany) to discuss the rationale and methodology of the the clinical trial programme for Mannan conjugated birch pollen allergoids, the efficacy and safety findings so […]

    Allergic Conditions
    Developed by Touch
    Ralph Mösges, AAAAI 2023: Immunotherapy for the treatment of birch pollen allergy
    Watch Time: 4 mins

    Allergen immunotherapy aims to treat an allergic response by reducing the production of IgE antibodies by the immune system, this is done by desensitising the patient to the allergen extract. It was a pleasure to talk with Prof. Ralph Mösges (University of Cologne, Cologne, Germany) around the impact immunotherapy has already had on the treatment […]

    Allergic Conditions
    Developed by Touch
    Luis Felipe C. Ensina, AAAAI 2023: Ligelizumab for the treatment of chronic spontaneous urticaria – findings from PEARL-1 and PEARL-2
    Watch Time: 5 mins

    Ligelizumab is a monoclonal antibody recently investigated in the phase 3 PEARL-1 and PEARL-2 studies for the treatment of chronic spontaneous urticaria (ClinicalTrials.gov Identifiers: NCT03580369 & NCT03580356). In this touchIMMUNOLOGY interview, we spoke with Dr. Luis Felipe C. Ensina (Federal University of São Paulo, São Paulo, Brazil) around the rationale for investigating ligelizumab in this […]

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72